Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada

INTRODUCTION: Pneumococcal conjugate vaccines (PCVs) have been available in Canada since 2001, with 13-valent PCV (PCV13) added to the infant routine immunization program throughout all Canadian provinces by 2011. The use of PCVs has dramatically reduced the burden of pneumococcal disease in Canada....

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Michele, Wasserman, Matt, Jadavi, Taj, Postma, Maarten, Breton, Marie-Claude, Peloquin, Francois, Earnshaw, Stephanie, McDade, Cheryl, Sings, Heather, Farkouh, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098750/
https://www.ncbi.nlm.nih.gov/pubmed/29934878
http://dx.doi.org/10.1007/s40121-018-0206-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098750/
https://www.ncbi.nlm.nih.gov/pubmed/29934878
http://dx.doi.org/10.1007/s40121-018-0206-1

Ejemplares similares